- Almotriptan tablet
- Almotriptan side effects
- Almotriptan serious side effects
- Almotriptan brand name
- Almotriptan dosage
- Almotriptan dosage forms
- Almotriptan almotriptan side effects
- Almotriptan mg
- Almotriptan oral dose
- Almotriptan drug
- Almotriptan 1000 mg
- Almotriptan 150 mg
- Almotriptan action
- Almotriptan 250 mg
How should this medicine be used?
Almotriptan comes as a tablet to take by mouth. It is usually taken at the first sign of a migraine headache. If your symptoms improve after you take almotriptan but return after 2 hours or longer, you may take a second tablet. However, if your symptoms do not improve after you take almotriptan, do not take a second tablet before calling your doctor. Your doctor will tell you the maximum number of tablets you may take in a 24-hour period. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take almotriptan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
You may take your first dose of almotriptan in a doctor's office or other medical facility where you can be monitored for serious reactions.
Call your doctor if your headaches do not get better or occur more frequently after taking almotriptan.
If you take almotriptan more often or for longer than the recommended period of time, your headaches may get worse or may occur more frequently. You should not take almotriptan or any other headache medication for more than 10 days per month. Call your doctor if you need to take almotriptan to treat more than four headaches in a 1-month period.
Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.
What should I know about storage and disposal of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
Keep your medicine in a safe place where children cannot reach it. It may be harmful to children. Store your medicine away from heat, light, or moisture at a controlled room temperature. If your medicine has expired, throw it away as instructed. If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to do so. Throw away your medicine as instructed. Be sure that discarded tablets are out of the reach of children.
How should I take almotriptan?
Your doctor may want to give your first dose of this medicine in a hospital or clinic setting to quickly treat any serious side effects that occur.
Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.
Take almotriptan as soon as you notice migraine symptoms.
After taking a tablet: If your headache goes away and comes back, take a second tablet 2 hours after the first. Do not take more than 2 tablets of almotriptan tablets in 24 hours. If your symptoms have not improved, contact your doctor before taking any more tablets.
Call your doctor if your headache does not go away at all after taking the first almotriptan tablet.
Never use more than your recommended dose. Overuse of migraine headache medicine can make headaches worse.
Contact your doctor if you have more than four headaches in one month (30 days). Tell your doctor if this medicine seems to stop working as well in treating your migraine attacks.
If you use almotriptan long-term, your heart function may need to be checked using an electrocardiograph or ECG (sometimes called an EKG). This will help your doctor determine if it is still safe for you to take almotriptan.
Store at room temperature away from moisture, heat, and light.
Commonly used brand name(s)
In the U.S.
Available Dosage Forms:
Therapeutic Class: Antimigraine
Pharmacologic Class: Serotonin Receptor Agonist, 5-HT1
almotriptan Side Effects
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:Less common
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- chest pain
- discharge from the eye
- eye irritation
- fast, irregular, pounding, or racing heartbeat or pulse
- itching, redness, or swelling of the skin
- neck pain or rigid neck
- redness of the inner lining of the eyelid
- skin rash
- shortness of breath
- tightness in the throat
- Abdominal or stomach cramping or pain
- black, tarry stools
- blood in the stools
- bringing back up of food
- chest pain, severe
- cool, pale skin
- difficulty with swallowing
- heartburn, repeated
- increased sweating
- loss of appetite
- loss of vision
- rapid breathing
- tightness in the chest
- weight loss
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Burning, numbness, prickly, or tingling feeling
- dry mouth
- Aching, fullness, or tension in the sinuses
- anxious feeling
- back pain
- change in sense of taste
- cough producing mucus
- decreased sensitivity to touch
- feeling of constant movement of self or surroundings
- feeling of spinning
- feeling of warmth or heat
- flushing or redness of the skin
- increased sense of hearing
- lack or loss of strength
- muscle aches or weakness
- painful menstrual period
- quivering or trembling
- runny or stuffy nose
- sore throat
- trouble sleeping
- Abnormal increase in reflexes
- abnormally increased feeling of mental and physical well-being
- buzzing or ringing in the ears
- change in dreams or nightmares
- change in sense of smell
- change in sense of touch
- clumsiness or unsteadiness
- continuous, uncontrolled, back-and-forth or rolling eye movements
- difficulty in concentrating
- double vision
- dry eyes
- dry throat
- feeling of pins and needles
- increased sensitivity to sunlight
- increased thirst
- loss of voice
- mental depression
- muscle stiffness
- pain, redness, swelling, or warmth in the joints
- stabbing pain
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Warnings and Precautions
Risk of Myocardial Ischemia and Infarction and Other Adverse Cardiac Events
Cardiac Events and Fatalities with 5-HT1 Agonists
Serious adverse cardiac events, including acute myocardial infarction, have been reported within a few hours following administration of Almotriptan malate. Life-threatening disturbances of cardiac rhythm and death have been reported within a few hours following the administration of other triptans. Considering the extent of use of triptans in patients with migraine, the incidence of these events is extremely low.
Almotriptan malate can cause coronary vasospasm; at least one of these events occurred in a patient with no cardiac history and with documented absence of coronary artery disease. Because of the close proximity of the events to use of Almotriptan malate, a causal relationship cannot be excluded. Patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of coronary artery disease (CAD) or a predisposition to Prinzmetal’s variant angina before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur.
Premarketing Experience with Almotriptan Malate in Adults
Among the 3865 subjects/patients who received Almotriptan malate in premarketing clinical trials, one patient was hospitalized for observation after a scheduled electrocardiogram (ECG) was found to be abnormal (negative T-waves on the left leads) 48 hours after taking a single 6.25 mg dose of Almotriptan. The patient, a 48-year-old female, had previously taken 3 other doses for earlier migraine attacks. Myocardial enzymes at the time of the abnormal ECG were normal. The patient was diagnosed as having had myocardial ischemia and that she had a family history of coronary disease. An ECG performed 2 days later was normal, as was a follow-up coronary angiography. The patient recovered without incident.
Postmarketing Experience with Almotriptan Malate in Adults
Serious cardiovascular events have been reported in association with the use of Almotriptan malate. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to definitively determine the proportion of the reported cases that were actually caused by Almotriptan or to reliably assess causation in individual cases [see Adverse Reactions (6.3)].
Patients with Documented Coronary Artery Disease
Because of the potential of this class of compound (5-HT1 agonists) to cause coronary vasospasm, Almotriptan malate should not be given to patients with documented ischemic or vasospastic coronary artery disease [see Contraindications (4.1)].
Patients with Risk Factors for CAD
It is strongly recommended that Almotriptan malate not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is modest, at best. If, during the cardiovascular evaluation, the patient’s medical history, electrocardiographic or other investigations reveal findings indicative of, or consistent with, coronary artery vasospasm or myocardial ischemia, Almotriptan malate should not be administered [see Contraindications (4.1)].
For patients with risk factors predictive of CAD, who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of Almotriptan malate take place in the setting of a physician’s office or similar medically staffed and equipped facility unless the patient has previously received Almotriptan malate. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an ECG during the interval immediately following Almotriptan malate, in these patients with risk factors. It is recommended that patients who are intermittent long-term users of Almotriptan malate and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use Almotriptan malate.
The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to Almotriptan malate. The ability of cardiac diagnostic procedures to detect all cardiovascular diseases or predisposition to coronary artery vasospasm is modest at best. Cardiovascular events associated with triptan treatment have occurred in patients with no cardiac history and with documented absence of coronary artery disease.
Sensations of Pain, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw
As with other 5-HT1 agonists, sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported after treatment with Almotriptan malate. Because 5-HT1 agonists may cause coronary vasospasm, patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of CAD or a predisposition to Prinzmetal’s variant angina before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms occur. Patients shown to have CAD and those with Prinzmetal’s variant angina should not receive 5-HT1 agonists [see Contraindications (4.1) and Warnings and Precautions (5.1)].
Cerebrovascular Events and Fatalities
Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with other triptans and some events have resulted in fatalities. In a number of cases, it appeared possible that the cerebrovascular events were primary, the triptan having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not. As with other acute migraine therapies, before treating headaches in patients not previously diagnosed as migraineurs and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. It should be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, and transient ischemic attack) [see Contraindications (4.2)].
Other Vasospasm-Related Events, Including Peripheral Vascular Ischemia and Colonic Ischemia
Triptans, including Almotriptan malate, may cause vasospastic reactions other than coronary artery vasospasm, such as peripheral and gastrointestinal vascular ischemia with abdominal pain and bloody diarrhea. Very rare reports of transient and permanent blindness and significant partial vision loss have been reported with the use of triptans. Visual disorders may also be part of a migraine attack. Patients who experience symptoms or signs suggestive of decreased arterial flow following the use of any triptan, such as ischemic bowel syndrome or Raynaud’s syndrome, are candidates for further evaluation [see Contraindications (4.3)].
The development of a potentially life-threatening serotonin syndrome may occur with triptans, including Almotriptan malate, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitant treatment with Almotriptan malate and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) [see Drug Interactions (7.3)].
Medication Overuse Headache
Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
Increases in Blood Pressure
As with other triptans, significant elevations in systemic blood pressure have been reported on rare occasions with Almotriptan malate use, in patients with and without a history of hypertension; very rarely these increases in blood pressure have been associated with significant clinical events. Almotriptan malate is contraindicated in patients with uncontrolled hypertension [see Contraindications (4.4)]. In normotensive healthy subjects and patients with hypertension controlled by medication, small, but clinically insignificant, increases in mean systolic (0.21 and 4.87 mm Hg, respectively) and diastolic (1.35 and 0.26 mm Hg, respectively) blood pressure relative to placebo were seen over the first 4 hours after oral administration of 12.5 mg of Almotriptan.
An 18% increase in mean pulmonary artery pressure was seen following dosing with another triptan in a study evaluating subjects undergoing cardiac catheterization.
Hypersensitivity to Sulfonamides
Caution should be exercised when prescribing Almotriptan malate to patients with known hypersensitivity to sulfonamides. The chemical structure of Almotriptan contains a sulfonyl group, which is structurally different from a sulfonamide. Cross-sensitivity to Almotriptan in patients allergic to sulfonamides has not been systematically evaluated.
Impaired Hepatic or Renal Function
Almotriptan malate should be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs, such as those with impaired hepatic or renal function [see Dosage and Administration (2.2), (2.3) and Clinical Pharmacology (12.3)].
Binding to Melanin-Containing Tissues
When pigmented rats were given a single oral dose of 5 mg/kg of radiolabeled Almotriptan, the elimination half-life of radioactivity from the eye was 22 days. This finding suggests that Almotriptan and/or its metabolites may bind to melanin in the eye. Because Almotriptan could accumulate in melanin-rich tissues over time, there is the possibility that it could cause toxicity in these tissues with extended use. However, no adverse retinal effects related to treatment with Almotriptan were noted in a 52-week toxicity study in dogs given up to 12.5 mg/kg/day (resulting in exposure [AUC] to parent drug approximately 20 times that in humans receiving the maximum recommended human dose of 25 mg/day). Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long-term ophthalmologic effects.
Three male dogs (out of a total of 14 treated) in a 52-week toxicity study of oral Almotriptan developed slight corneal opacities that were noted after 51 weeks, but not after 25 weeks of treatment. The doses at which this occurred were 2, 5, and 12.5 mg/kg/day. The opacity reversed after a 4-week drug-free period in the affected dog treated with the highest dose. Systemic exposure (plasma AUC) to parent drug at 2 mg/kg/day was approximately 2.5 times the exposure in humans receiving the maximum recommended human daily dose of 25 mg. A no-effect dose was not established.
Serious cardiac reactions, including myocardial infarction, have occurred following the use of Almotriptan malate tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD. Reactions reported in association with triptans have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation [see Contraindications (4.1) and Warnings and Precautions (5.1)].
The following adverse reactions are discussed in more detail in other sections of the labeling:• Risk of Myocardial Ischemia and Infarction and Other Adverse Cardiac Events [see Warnings and Precautions (5.1)] • Sensations of Pain, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw [see Warnings and Precautions (5.2)] • Cerebrovascular Events and Fatalities [see Warnings and Precautions (5.3)] • Other Vasospasm-Related Events, including Peripheral Vascular Ischemia and Colonic Ischemia [see Warnings and Precautions (5.4)] • Serotonin Syndrome [see Warnings and Precautions (5.5)] • Increases in Blood Pressure [see Warnings and Precautions (5.7)]
Adverse events were assessed in controlled clinical trials that included 1840 adult patients who received one or two doses of Almotriptan malate and 386 adult patients who received placebo. The most common adverse reactions during treatment with Almotriptan malate were nausea, somnolence, headache, paresthesia, and dry mouth. In long-term open-label studies where patients were allowed to treat multiple attacks for up to 1 year, 5% (63 out of 1347 patients) withdrew due to adverse experiences.
Adverse events were assessed in controlled clinical trials that included 362 adolescent patients who received Almotriptan malate and 172 adolescent patients who received placebo. The most common adverse reactions during treatment with Almotriptan malate were dizziness, somnolence, headache, paresthesia, nausea, and vomiting. In a long-term, open-label study where patients were allowed to treat multiple attacks for up to 1 year, 2% (10 out of 420 adolescent patients) withdrew due to adverse events.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Almotriptan Malate Clinical Trials
Table 1 lists the adverse events that occurred in at least 1% of the adult patients treated with Almotriptan malate, and at an incidence greater than in patients treated with placebo, regardless of drug relationship.
Almotriptan 6.25 mg
(n = 527)
Almotriptan 12.5 mg
(n = 1313)
(n = 386)
Nervous System Disorders
The incidence of adverse events in controlled clinical trials was not affected by gender, weight, age, presence of aura, or use of prophylactic medications or oral contraceptives. There were insufficient data to assess the effect of race on the incidence of adverse events.
Table 2 lists the adverse reactions reported by 1% or more of Almotriptan malate-treated adolescents age 12 to 17 years in 1 placebo-controlled, double-blind clinical trial.
Almotriptan 6.25 mg
(n = 180)
Almotriptan 12.5 mg
(n = 182)
(n = 172)
Nervous System Disorders
Other Adverse Reactions Observed in Almotriptan Malate Clinical Trials
In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. The reports include adverse reactions in 5 adult controlled studies and 1 adolescent controlled study. Variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Reaction frequencies are calculated as the number of patients who used Almotriptan malate and reported a reaction divided by the total number of patients exposed to Almotriptan malate (n = 3047, all doses). All reported reactions are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Reactions are further classified within system organ class and enumerated in order of decreasing frequency using the following definitions: frequent adverse reactions are those occurring in 1/100 or more patients, infrequent adverse reactions are those occurring in fewer than 1/100 to 1/1000 patients, and rare adverse reactions are those occurring in fewer than 1/1000 patients.
Body: Frequent: Headache. Infrequent: Abdominal cramp or pain, Asthenia, Chills, Back pain, Chest pain, Neck pain, Fatigue, and Rigid neck. Rare: Fever and Photosensitivity reaction.
Cardiovascular: Infrequent: Vasodilation, Palpitations, and Tachycardia. Rare: Hypertension and Syncope.
Digestive: Infrequent: Diarrhea, Vomiting, Dyspepsia, Gastroenteritis and Increased thirst. Rare: Colitis, Gastritis, Esophageal reflux, and Increased salivation.
Metabolic: Infrequent: Hyperglycemia and Increased serum creatine phosphokinase. Rare: Increased gamma glutamyl transpeptidase and Hypercholesteremia.
Musculo-Skeletal: Infrequent: Myalgia. Rare: Arthralgia, Arthritis, Myopathy and Muscle weakness.
Nervous: Frequent: Dizziness and Somnolence. Infrequent: Tremor, Vertigo, Anxiety, Hypoesthesia, Restlessness, CNS stimulation, and Shakiness. Rare: Change in dreams, Impaired concentration, Abnormal coordination, Depressive symptoms, Euphoria, Hyperreflexia, Hypertonia, Nervousness, Neuropathy, Nightmares, Nystagmus and Insomnia.
Respiratory: Infrequent: Pharyngitis, Rhinitis, Dyspnea, Laryngismus, Sinusitis and Bronchitis. Rare: Hyperventilation, Laryngitis, Sneezing and Epistaxis.
Skin: Infrequent: Diaphoresis, Pruritus, and Rash. Rare: Dermatitis and Erythema.
Special Senses: Infrequent: Ear pain and Tinnitus. Rare: Diplopia, Dry eyes, Eye pain, Otitis media, Parosmia, Scotoma, Conjunctivitis, Eye irritation, Hyperacusis and Taste alteration.
Urogenital: Infrequent: Dysmenorrhea.
The following adverse reactions have been identified during postapproval use of Almotriptan malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune System Disorders: Hypersensitivity reactions (including angioedema, anaphylactic reactions and anaphylactic shock)
Psychiatric disorders: Confusional state, Restlessness
Nervous System Disorders: Hemiplegia, Hypoesthesia, Seizures
Eye Disorders: Blepharospasm, Visual impairment, Vision blurred
Ear and Labyrinth Disorders: vertigo
Cardiac Disorders: Acute myocardial infarction, Coronary artery vasospasm, Angina pectoris, Tachycardia
Gastrointestinal Disorders: Abdominal discomfort, Abdominal pain, Abdominal pain upper, Colitis, Hypoesthesia oral, Swollen tongue
Skin and Subcutaneous Tissue Disorders: Cold sweat, Erythema, Hyperhidrosis
Musculoskeletal, Connective Tissue, and Bone Disorders: Arthralgia, Myalgia, Pain in extremity
Reproductive System and Breast Disorders: Breast pain
General Disorders: Malaise, Peripheral coldness.
These drugs have been reported to cause prolonged vasospastic reactions. Because, in theory, vasospastic effects may be additive, ergotamine-containing or ergot-type medications (like dihydroergotamine, ergotamine tartrate, or methysergide) and Almotriptan malate should not be used within 24 hours of each other [see Contraindications (4.5)].
5-HT1 Agonists (e.g., Triptans)
Concomitant use of other 5-HT1 agonists (e.g., triptans) within 24 hours of treatment with Almotriptan malate is contraindicated [see Contraindications (4.6)].
Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors
Cases of life-threatening serotonin syndrome have been reported during combined use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.5), Clinical Pharmacology (12.3)].
Ketoconazole and Other Potent CYP3A4 Inhibitors
Coadministration of Almotriptan and oral ketoconazole, a potent CYP3A4 inhibitor, resulted in an approximately 60% increase in exposure of Almotriptan. Increased exposures to Almotriptan may be expected when Almotriptan is used concomitantly with other potent CYP3A4 inhibitors [see Clinical Pharmacology (12.3)].
In patients concomitantly using potent CYP3A4 inhibitors, the recommended starting dose of Almotriptan is 6.25 mg. The maximum daily dose should not exceed 12.5 mg within a 24-hour period. Concomitant use of Almotriptan malate and potent CYP3A4 inhibitors should be avoided in patients with renal or hepatic impairment [see Clinical Pharmacology (12.3)].
Use in specific populations
Pregnancy Category C
In animal studies, Almotriptan produced developmental toxicity (increased embryolethality and fetal skeletal variations, and decreased offspring body weight) at doses greater than those used clinically. There are no adequate and well-controlled studies in pregnant women; therefore, Almotriptan malate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
When Almotriptan (125, 250, 500, or 1000 mg/kg/day) was administered orally to pregnant rats throughout the period of organogenesis, increased incidences of fetal skeletal variations (decreased ossification) were noted at a dose of 250 mg/kg/day or greater and an increase in embryolethality was seen at the highest dose. The no-effect dose for embryo-fetal developmental toxicity in rats (125 mg/kg/day) is approximately 100 times the maximum recommended human dose (MRHD) of 25 mg/day on a body surface area (mg/m2) basis. Similar studies in pregnant rabbits conducted with Almotriptan (oral doses of 5, 20, or 60 mg/kg/day) demonstrated increases in embryolethality at the highest dose. The no-effect dose for embryo-fetal developmental toxicity in rabbits (20 mg/kg/day) is approximately 15 times the MRHD on a mg/m2 basis. When Almotriptan (25, 100, or 400 mg/kg/day) was administered orally to rats throughout the periods of gestation and lactation, gestation length was increased and litter size and offspring body weight were decreased at the highest dose. The decrease in pup weight persisted throughout lactation. The no-effect dose in this study (100 mg/kg/day) is 40 times the MRHD on a mg/m2 basis.
Labor and Delivery
The effect of Almotriptan malate on labor and delivery in humans is unknown.
It is not known whether Almotriptan is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Almotriptan malate is administered to a nursing woman. Levels of Almotriptan in rat milk were up to 7 times higher than in rat plasma.
Safety and efficacy of Almotriptan malate in pediatric patients under the age of 12 years have not been established. The pharmacokinetics, efficacy, and safety of Almotriptan malate have been evaluated in adolescent patients, age 12 to 17 years [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)].
In a clinical study, Almotriptan 6.25 mg and 12.5 mg were found to be effective for the relief of migraine headache pain in adolescent patients age 12 to 17 years. Efficacy on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. The most common adverse reactions (incidence of ≥ 1%) associated with Almotriptan malate treatment were dizziness, somnolence, headache, paresthesia, nausea, and vomiting [see Adverse Reactions (6.1)]. The safety and tolerability profile of Almotriptan malate treatment in adolescents is similar to the profile observed in adults.
Postmarketing experience with other triptans include a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults.
Clinical studies of Almotriptan malate did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. Clearance of Almotriptan was lower in elderly volunteers than in younger individuals, but there were no observed differences in the safety and tolerability between the two populations [see Clinical Pharmacology (12.3)]. In general, dose selection for an elderly patient should be cautious, usually starting at the low dose, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The recommended dose of Almotriptan malate for elderly patients with normal renal function for their age is the same as that recommended for younger adults.
The recommended starting dose of Almotriptan in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].
The recommended starting dose of Almotriptan in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
Signs and Symptoms
Patients and volunteers receiving single oral doses of 100 to 150 mg of Almotriptan did not experience significant adverse events. Six additional normal volunteers received single oral doses of 200 mg without serious adverse events. During clinical trials with Almotriptan, one patient ingested 62.5 mg in a 5-hour period and another patient ingested 100 mg in a 38-hour period. Neither patient experienced adverse reactions.
Based on the pharmacology of triptans, hypertension or other more serious cardiovascular symptoms could occur after overdosage.
There is no specific antidote to Almotriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.
Clinical and electrocardiographic monitoring should be continued for at least 20 hours even if clinical symptoms are not observed.
It is unknown what effect hemodialysis or peritoneal dialysis has on plasma concentrations of Almotriptan.
Almotriptan malate tablets contain Almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine(±)-hydroxybutanedioate (1:1), and its structural formula is:
C17H25N3O2S-C4H6O5 M.W. 469.56
Almotriptan is a white to off white crystalline powder that is soluble in water. Almotriptan malate tablets for oral administration contain Almotriptan malate equivalent to 6.25 mg or 12.5 mg of Almotriptan. Each compressed tablet contains the following inactive ingredients: croscarmellose sodium, hypromellose, macrogol/PEG 8000, mannitol, microcrystalline cellulose, polydextrose FCC, povidone, sodium stearyl fumarate, titanium dioxide, and triacetin/glycerol triacetate.
Almotriptan - Clinical Pharmacology
Mechanism of Action
Almotriptan binds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors. Almotriptan has weak affinity for 5-HT1A and 5-HT7 receptors, but has no significant affinity or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, 5-HT6; alpha or beta adrenergic; adenosine (A1, A2); angiotensin (AT1, AT2); dopamine (D1, D2); endothelin (ETA, ETB); or tachykinin (NK1, NK2, NK3) binding sites.
Current theories on the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of vasoactive and pro-inflammatory peptides from sensory nerve endings in an activated trigeminal system. The therapeutic activity of Almotriptan in migraine can most likely be attributed to agonist effects at 5-HT1B/1D receptors on the extracerebral, intracranial blood vessels that become dilated during a migraine attack and on nerve terminals in the trigeminal system. Activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release, and reduced transmission in trigeminal pain pathways.
The absolute bioavailability of Almotriptan is about 70%, with peak plasma levels occurring 1 to 3 hours after administration; food does not affect pharmacokinetics.
Almotriptan is minimally protein bound (approximately 35%) and the mean apparent volume of distribution is approximately 180 to 200 liters.
Almotriptan is metabolized by two major and one minor pathways. Monoamine oxidase (MAO)-mediated oxidative deamination (approximately 27% of the dose), and cytochrome P450-mediated oxidation (approximately 12% of the dose) are the major routes of metabolism, while flavin monooxygenase is the minor route. MAO-A is responsible for the formation of the indoleacetic acid metabolite, whereas cytochrome P450 (3A4 and 2D6) catalyzes the hydroxylation of the pyrrolidine ring to an intermediate that is further oxidized by aldehyde dehydrogenase to the gamma-aminobutyric acid derivative. Both metabolites are inactive.
Almotriptan has a mean half-life of 3 to 4 hours. Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Renal clearance exceeds the glomerular filtration rate by approximately 3-fold, indicating an active mechanism. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.
All drug interaction studies were performed in healthy volunteers using a single 12.5 mg dose of Almotriptan and multiple doses of the other drug.
Monoamine Oxidase Inhibitors
Coadministration of Almotriptan and moclobemide (150 mg twice daily for 8 days) resulted in a 27% decrease in Almotriptan clearance and an increase in Cmax of approximately 6%. No dose adjustment is necessary.
Coadministration of Almotriptan and propranolol (80 mg twice daily for 7 days) resulted in no significant changes in the pharmacokinetics of Almotriptan.
Coadministration of Almotriptan and fluoxetine (60 mg daily for 8 days), a potent inhibitor of CYP2D6, had no effect on Almotriptan clearance, but maximal concentrations of Almotriptan were increased 18%. This difference is not clinically significant.
Coadministration of Almotriptan and verapamil (120 mg sustained-release tablets twice daily for 7 days), an inhibitor of CYP3A4, resulted in a 20% increase in the area under the plasma concentration-time curve, and in a 24% increase in maximal plasma concentrations of Almotriptan. Neither of these changes is clinically significant. No dose adjustment is necessary.
Ketoconazole and Other Potent CYP3A4 Inhibitors
Coadministration of Almotriptan and ketoconazole, a potent CYP3A4 inhibitor, resulted in an approximately 60% increase in exposure of Almotriptan. Increased exposures to Almotriptan may be expected when Almotriptan is used with other potent CYP3A4 inhibitors.
Renal and total clearance, and amount of drug excreted in the urine, were lower in elderly healthy volunteers (age 65 to 76 years) than in younger healthy volunteers (age 19 to 34 years), resulting in longer terminal half-life (3.7 hours vs. 3.2 hours) and a 25% higher area under the plasma concentration-time curve in the elderly subjects. The differences, however, do not appear to be clinically significant.
A pharmacokinetics study of Almotriptan was conducted in adolescents (12 to 17 years) and adults (18 to 55 years) with or without a history of migraine. No differences were observed in the rate or extent of absorption of Almotriptan in adolescents compared with adults.
No significant gender differences were observed in pharmacokinetic parameters.
No significant differences were observed in pharmacokinetic parameters between Caucasian and African-American volunteers.
The pharmacokinetics of Almotriptan have not been assessed in patients with hepatic impairment. Based on the known mechanisms of clearance of Almotriptan, the maximum decrease expected in Almotriptan clearance due to hepatic impairment would be 60% [see Dosage and Administration (2.2)].
The clearance of Almotriptan was approximately 65% lower in patients with severe renal impairment (Cl/F = 19.8 L/hour; creatinine clearance between 10 and 30 mL/min) and approximately 40% lower in patients with moderate renal impairment (Cl/F = 34.2 L/hour; creatinine clearance between 31 and 71 mL/min) than in healthy volunteers (Cl/F = 57 L/hour). Maximal plasma concentrations of Almotriptan increased by approximately 80% in these patients [see Dosage and Administration (2.3)].
Carcinogenesis, Mutagenesis, Impairment of Fertility
Almotriptan was administered to mice and rats for up to 103 to 104 weeks at oral doses up to 250 mg/kg/day and 75 mg/kg/day, respectively. These doses were associated with plasma exposures (AUC) to parent drug that were approximately 40 and 80 times, in mice and rats respectively, the plasma AUC in humans at the maximum recommended human dose (MRHD) of 25 mg/day. Because of high mortality rates in both studies, which reached statistical significance in high-dose female mice, all female rats, all male mice, and high-dose female mice were terminated between weeks 96 and 98. There was no increase in tumors related to Almotriptan administration.
Almotriptan was not mutagenic in two in vitro gene mutation assays, the Ames test, and the mouse lymphoma tk assay. Almotriptan was not clastogenic in an in vivo mouse micronucleus assay.
Impairment of Fertility
When male and female rats received Almotriptan (25, 100, or 400 mg/kg/day) orally prior to and during mating and gestation, prolongation of the estrous cycle was observed at the mid-dose and greater, and fertility was impaired at the highest dose. Subsequent mating of treated with untreated animals indicated that the decrease in fertility was due to an effect on females. The no-effect dose for reproductive toxicity in rats (25 mg/kg/day) is approximately 10 times the MRHD on a mg/m2 basis.
- Almotriptan Malate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral, as maleate:
Axert: 6.25 mg
Axert: 12.5 mg [contains fd&c blue #2 (indigotine)]
Generic: 6.25 mg, 12.5 mg
Migraine: Oral: Initial: 6.25-12.5 mg in a single dose; if the headache returns, repeat the dose after 2 hours; no more than 2 doses (maximum daily dose: 25 mg)
Note: The safety of treating more than 4 migraines/month has not been established.
Dosage adjustment with concomitant use of an enzyme inhibitor:
Patients receiving a potent CYP3A4 inhibitor: Initial: 6.25 mg in a single dose; maximum daily dose: 12.5 mg
Patients with renal impairment and concomitant use of a potent CYP3A4 inhibitor: Avoid use
Patients with hepatic impairment and concomitant use of a potent CYP3A4 inhibitor: Avoid use
Data not available.